Accéder au contenu
Merck
Toutes les photos(1)

Principaux documents

Voir toute la documentation

SML2357

Sigma-Aldrich

Isavuconazole

≥98% (HPLC), powder, fungal sterol biosynthesis inhibitor

Synonyme(s) :

(2R,3R)-3-[4-(4-Cyanophenyl)thiazol-2-yl]-2-(2,5-difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, 1-[(2R,3R)-3-[4-(4-Cyanophenyl)thiazol-2-yl]-2-(2,5-difluorophenyl)-2-hydroxybutyl]-1,2,4-triazole, 4-[2-[(1R,2R)-2-(2,5-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl]-4-thiazolyl]benzonitrile, BAL 4815, RO 0094815

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C22H17F2N5OS
Numéro CAS:
241479-67-4
Poids moléculaire :
437.47
Numéro MDL:
MFCD06407745
Code UNSPSC :
12352200
Nomenclature NACRES :
NA.77

Nom du produit

Isavuconazole, ≥98% (HPLC)

Essai

≥98% (HPLC)

Forme

powder

Couleur

white to beige

Solubilité

DMSO: 2 mg/mL, clear

Température de stockage

2-8°C

Chaîne SMILES 

Fc1c(cc(cc1)F)[C@](O)([C@@H](C)c3[s]cc(n3)c4ccc(cc4)C#N)C[n]2ncnc2

InChI

1S/C22H17F2N5OS/c1-14(21-28-20(10-31-21)16-4-2-15(9-25)3-5-16)22(30,11-29-13-26-12-27-29)18-8-17(23)6-7-19(18)24/h2-8,10,12-14,30H,11H2,1H3/t14-,22+/m0/s1

Clé InChI

DDFOUSQFMYRUQK-RCDICMHDSA-N

Application

Isavuconazole has been used as an antifungal agent to test its effect on Mucor circinelloides gene transcription. It has also been used
to analyze its in vitro activity against isolates from the R. argillacea species complex A. fumigatus, N. hiratsukae and C. parapsilosis.

Actions biochimiques/physiologiques

Isavuconazole is a triazole antifungal drug. It inhibits fungal sterol biosynthesis by inhibition of cytochrome P450 sterol 14-α-demethylase (CYP51), an enzyme in the sterol biosynthesis pathway that leads from lanosterol to ergosterol. It has been approved for the treatment of both invasive aspergillosis and invasive mucormycosis.

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Warning

Mentions de danger

H361fd

Classification des risques

Repr. 2

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number
0000370819
0000352642
0000354449
0000327988
0000327989

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Rechercher un(e) COA

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

J Steinmann et al.
Antimicrobial agents and chemotherapy, 60(11), 6890-6891 (2016-08-17)
The in vitro susceptibilities to the novel triazole isavuconazole and six other antifungal agents of a large collection of Rasamsonia isolates (n = 47) belonging to seven species were determined. Isavuconazole and voriconazole had no in vitro activity (MIC, >32
M-P Ledoux et al.
Journal de mycologie medicale, 28(1), 15-22 (2018-03-20)
Isavuconazole, the active moiety of its prodrug isavuconazonium, is a new extended-spectrum triazole whose activity against yeasts, molds, including Aspergillus and mucorales, and dimorphic fungi has been shown in vitro and in preclinical models. The most relevant pharmacokinetics features are
Jeffrey M Rybak et al.
Pharmacotherapy, 35(11), 1037-1051 (2015-11-26)
Coinciding with the continually increasing population of immunocompromised patients worldwide, the incidence of invasive fungal infections has grown over the past 4 decades. Unfortunately, infections caused by both yeasts such as Candida and molds such as Aspergillus or Mucorales remain
A Prigitano et al.
The Journal of hospital infection, 123, 74-79 (2022-02-20)
Preventing and reducing nosocomial infections is a public health goal. Concern about healthcare-associated fungal infections has increased in recent years due to the emergence and spread of new pathogens, increasing antifungal resistance and outbreaks in hospital settings. To investigate the
Seyedmojtaba Seyedmousavi et al.
Antimicrobial agents and chemotherapy, 59(5), 2855-2866 (2015-03-11)
Azole resistance is an emerging problem in Aspergillus fumigatus which translates into treatment failure. Alternative treatments with new azoles may improve therapeutic outcome in invasive aspergillosis (IA) even for strains with decreased susceptibility to current azoles. The in vivo efficacy

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique